Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
暂无分享,去创建一个
Deepak L. Bhatt | Lawrence A Leiter | E. Braunwald | N. Desai | B. Scirica | Darren K Mcguire | P. Steg | J. Udell | S. Wiviott | I. Raz | J. Davidson | R. Frederich | K. Ray | Elaine B. Hoffman | B. Hirshberg | M. Cavender | Ofri Mosenzon | P. Ohman
[1] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.
[2] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.
[3] F. Wolf,et al. Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.
[4] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[5] Deepak L. Bhatt,et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial , 2013, Diabetes/metabolism research and reviews.
[6] S. Kahn. Incretin Therapy and Islet Pathology: A Time for Caution , 2013, Diabetes.
[7] M. Nauck. A Critical Analysis of the Clinical Use of Incretin-Based Therapies , 2013, Diabetes Care.
[8] R. Elashoff,et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies , 2013, Diabetes Care.
[9] Jodi B Segal,et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. , 2013, JAMA internal medicine.
[10] A. Scheen,et al. Cardiovascular effects of gliptins , 2013, Nature Reviews Cardiology.
[11] M. Monami,et al. Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.
[12] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[13] M. Rutter,et al. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure , 2013, Heart Failure Reviews.
[14] V. Basevi. Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.
[15] Deepak L. Bhatt,et al. Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus , 2012, Clinical cardiology.
[16] M. Woodward,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.
[17] T. Wilt,et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] M. Woodward,et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] Marcello Tonelli,et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.
[20] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.
[21] L. Schiöler,et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register , 2012, BMJ Open.
[22] M. Kuro-o,et al. The emerging role of Klotho in clinical nephrology. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[24] T. Wilt,et al. Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline , 2012, Annals of Internal Medicine.
[25] Deepak L. Bhatt,et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. , 2011, American heart journal.
[26] H. Yokoyama,et al. Pioglitazone reduces urinary albumin excretion in renin−angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study , 2011, Clinical and Experimental Nephrology.
[27] F. Gueyffier,et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[28] K. Lipska,et al. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.
[29] M. S. Kirkman,et al. Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.
[30] D. Boulton,et al. Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin , 2011, Clinical pharmacokinetics.
[31] L. Ruilope,et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.
[32] W. Herrington,et al. Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease? , 2011, Nephron Clinical Practice.
[33] Deepak L. Bhatt,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.
[34] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.
[35] P. Sarafidis,et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] K. Mahaffey,et al. A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes , 2010, Postgraduate medicine.
[37] G. Bakris,et al. Editorial Perspective. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial? , 2010, American Journal of Nephrology.
[38] Markolf Hanefeld,et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.
[39] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[40] I. Raz,et al. Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No , 2009, Diabetes Care.
[41] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[42] N. Sattar,et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.
[43] D. Levy,et al. Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005 , 2009, Circulation.
[44] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[45] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[46] V. Pavlicek. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials , 2009 .
[47] J. Nunnelee. Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572. , 2008 .
[48] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[49] Keith C. Norris,et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. , 2008, American heart journal.
[50] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[51] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[52] Darren K Mcguire,et al. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. , 2008, Circulation.
[53] A. Skene,et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.
[54] R. Nesto,et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.
[55] Deepak L. Bhatt,et al. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. , 2007, American heart journal.
[56] E. Topol,et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.
[57] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[58] D. Cryer,et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. , 2005, Diabetes care.
[59] A. Murray,et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.
[60] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[61] A. Collins,et al. Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.
[62] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[63] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[64] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[65] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[66] H. Heinzl,et al. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. , 1997, Computer methods and programs in biomedicine.
[67] R. Simon,et al. Flexible regression models with cubic splines. , 1989, Statistics in medicine.